• Aminopeptidase Inhibition Alters Angiotensin Signaling in Ra

  2026-07-15

  Harding and Felix's 1987 study demonstrated that inhibiting aminopeptidase activity with bestatin hydrochloride amplifies neuronal responses to angiotensin II and III in the rat brain. These results clarify enzymatic steps in neuropeptide signaling and provide a mechanistic foundation for future research on neurovascular regulation and peptide-targeted interventions.

• RIPA Lysis Buffer Strong: Enabling Precision in Translationa

  2026-07-15

  Translational immunology demands robust, customizable tools for protein extraction from complex tissues—especially when interrogating dynamic immunopathologies such as post-infarction T cell responses. This thought-leadership article explores how mechanistic understanding of immune checkpoint axes, as elucidated in recent nanovesicle research, intersects with strategic protocol design. By leveraging RIPA Lysis Buffer (Strong, without inhibitors), researchers can customize their lysis workflows for diverse downstream assays across immunology and cardiology. We contextualize APExBIO’s product in relation to emerging evidence, highlight protocol nuances, and offer strategic guidance for high-impact translational research.

• 2-Deoxy-D-glucose: Glycolysis Inhibition Benchmarks & Protoc

  2026-07-14

  2-Deoxy-D-glucose (2-DG) is a validated glycolysis inhibitor used to induce metabolic oxidative stress, disrupt ATP synthesis, and modulate cancer and viral cell metabolism. This article details verifiable mechanisms, quantitative cytotoxicity data, and practical workflow integration, focusing on its applications in KIT-positive gastrointestinal stromal tumor and non-small cell lung cancer research.

• CCG-1423: Precision RhoA Inhibitor for Advanced Cell Studies

  2026-07-14

  CCG-1423 empowers researchers to dissect RhoA/ROCK1 signaling with nanomolar precision, offering unique control over cell proliferation, invasion, and tight junction dynamics. Its selective MRTF-A/importin α/β1 disruption supports robust cancer and viral pathogenesis assays that surpass standard RhoA inhibitors.

• TG003 Cdc2-like Kinase Inhibitor: Precision Tool for Splicin

  2026-07-13

  Explore how TG003, a potent Cdc2-like kinase inhibitor, advances research in alternative splicing and platinum resistance. Discover unique protocol insights, mechanistic depth, and practical guidance for using TG003 in disease models.

• L1023 Anti-Cancer Compound Library: Transforming High-Throug

  2026-07-13

  The L1023 Anti-Cancer Compound Library empowers researchers to interrogate diverse oncogenic pathways using validated, ready-to-screen small molecules. With 1,164 pre-dissolved compounds targeting kinases, proteasomes, and epigenetic regulators, it streamlines high-throughput discovery and robust hit validation in cancer research.

• Mecamylamine Hydrochloride in Neuropsychiatric Disorder Rese

  2026-07-12

  Mecamylamine hydrochloride empowers researchers to dissect nicotinic acetylcholine receptor signaling in neuropsychiatric and gut-brain axis studies. This guide translates recent mechanistic breakthroughs into actionable protocols, highlighting troubleshooting tips and advanced workflow integration for maximum experimental reproducibility.

• ARCA Cy5 EGFP mRNA (5-moUTP) for Advanced Delivery Assays

  2026-07-10

  ARCA Cy5 EGFP mRNA (5-moUTP) streamlines direct, quantitative mRNA delivery and localization assays in mammalian cells by combining dual fluorescence with robust innate immune suppression. Its 5-methoxyuridine modification and ARCA capping set new standards for translation efficiency and reproducibility, making it an indispensable tool for modern mRNA delivery research.

• Applied Workflows with the BCA Protein Assay Kit: Precision

  2026-07-09

  The BCA Protein Assay Kit (K4101) from APExBIO delivers robust, highly sensitive protein quantification for complex molecular biology workflows. This article unpacks optimized experimental protocols, troubleshooting tactics, and key innovations—empowering researchers to achieve accurate, reproducible protein concentration measurements in even the most challenging samples.

• Dipeptidyl Peptidases & N-Degron Pathways in Protein Stabili

  2026-07-09

  This study reveals a cooperative mechanism between dipeptidyl peptidases (DPP8/9) and E3 ligases in the N-degron pathway for targeted protein degradation, especially of mislocalized secretory proteins. These insights advance understanding of protein quality control and provide a mechanistic basis for exploring DPP inhibition in disease contexts.

• Epidermal Growth Factor (EGF), Human Recombinant: Activity a

  2026-07-08

  Recombinant human EGF is a rigorously validated growth factor that drives cell proliferation and differentiation via high-affinity EGFR binding. APExBIO’s EGF (P1008) demonstrates ≥98% purity and potent biological activity in standardized cell-based assays. This article details molecular properties, benchmarks, and practical workflow parameters for reliable laboratory use.

• Precision Oncology: Advancing MCL1 Inhibitor Discovery with

  2026-07-08

  Explore how mechanistic insights into MCL1-mediated drug resistance in breast cancer, combined with strategic use of the L1023 Anti-Cancer Compound Library, are redefining translational and high-throughput oncology research. This article bridges recent breakthroughs in apoptosis targeting with actionable guidance for innovative screening campaigns, and provides protocol parameters for robust experimental design.

• MiR-3180 Suppresses HCC by Targeting Lipid Synthesis and Upt

  2026-07-07

  Hong et al. (2023) uncover that miR-3180 acts as a dual inhibitor of de novo fatty acid synthesis and lipid uptake in hepatocellular carcinoma (HCC) by directly suppressing SCD1 and CD36. These findings position miR-3180 as a promising prognostic marker and therapeutic target for metabolic intervention in HCC.

• Berberine Hydrochloride: Protocols for Gut-Bone Axis Researc

  2026-07-07

  Berberine hydrochloride empowers metabolic and osteoimmune studies with unique modulation of the gut-bone axis, as validated by recent reference studies. This guide provides protocol-driven insights, troubleshooting, and workflow optimization using high-purity material from APExBIO.

• Quantifying Drug-Induced Fractional Killing via High-Through

  2026-07-06

  Inde et al. present a robust protocol to quantify drug-induced fractional killing in cancer cell populations using high-throughput microscopy. This approach allows simultaneous assessment of hundreds of experimental conditions, deepening insights into variable responses to kinase inhibitors and supporting more reproducible cell death studies.

16270 records 1/1085 page Next 12345 下5页 Last page